Hoth Therapeutics has completed its transformation into Rocket One Inc., with shares now trading under the new Nasdaq ticker RKTO as of Thursday. The rebranding marks a strategic shift from biotech to a focus on artificial intelligence chips designed for space applications.
Market Reaction
Investors responded enthusiastically to the change. Pre-market trading saw RKTO shares climb 46.97% to $1.999 from Wednesday's close of $1.36. This follows a 92.09% surge in the previous session under the old HOTH ticker. The stock has more than doubled since the company first announced its pivot last week.
Strategic Pivot
Rocket One is targeting what it calls the "orbital economy," encompassing satellite systems, defense platforms, and space-based computing. The company claims exclusive rights to nanomagnetic AI chip technology, which uses nanoscale magnetism rather than traditional silicon-based electrical charge to process AI workloads more efficiently. The technology is also designed to be radiation-tolerant, addressing a key challenge for hardware operating in space.
CEO Robb Knie stated, "Space is moving from a launch story to a compute story." He emphasized that the RKTO ticker signals the company's commitment to the orbital economy to investors, partners, and customers.
Biotech Legacy Continues
Despite the name change and strategic pivot, Rocket One maintains its biotech pipeline. The company's drug candidates—including HT-001, HT-KIT, HT-ALZ, and a GDNF metabolic program—will continue development under a wholly owned subsidiary.
Financial Challenges
The company faces significant financial hurdles. In its latest quarterly report for the period ended March 31, Rocket One reported no revenue and a net loss of approximately $2.7 million. Cash and equivalents stood at about $4.0 million, with an accumulated deficit nearing $75.6 million. The company has warned that its available cash is insufficient to cover operating costs and capital needs for at least the next 12 months, raising substantial doubt about its ability to continue as a going concern.
Additionally, Nasdaq notified the company on April 30 that it fell short of the exchange's minimum $1 bid price listing standard. Rocket One has until October 27, 2026, to regain compliance by closing at or above $1 for at least 10 consecutive business days.
Capital Raising
To address funding needs, Rocket One filed an amended prospectus on Wednesday to register up to $2.66 million in additional common stock for sale through an at-the-market program. The company has already sold 6.82 million shares under this program, raising approximately $6.6 million.
Competitive Landscape
Rocket One enters a crowded space sector. Competitors like Rocket Lab, Intuitive Machines, and AST SpaceMobile have established commercial operations. Rocket One, however, has yet to confirm a commercial space product, making its entry into the public space stock arena a speculative bet on its technology's potential.
As regular trading opens, the market will test whether RKTO can sustain its gains, attract new investment without diluting existing shareholders, and prove it is more than a rebranded biotech company venturing into chips and orbital computing.
